1. Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF‐kB activity via mitochondrial ROS.
- Author
-
Jeffries, Nathan E., Sadreyev, Daniel, Trull, Elizabeth C., Chetal, Kashish, Yvanovich, Emma E., Mansour, Michael K., Sadreyev, Ruslan I., and Sykes, David B.
- Subjects
- *
ERYTHROCYTES , *IRON chelates , *MYELOID cells , *IRON overload , *GENE expression - Abstract
Summary The iron chelator deferasirox (DFX) is effective in the treatment of iron overload. In certain patients with myelodysplastic syndrome, DFX can also provide a dramatic therapeutic benefit, improving red blood cell production and decreasing transfusion requirements. Nuclear Factor‐kappa B (NF‐kB) signalling has been implicated as a potential mechanism behind this phenomenon, with studies focusing on the effect of DFX on haematopoietic progenitors. Here, we examine the phenotypic and transcriptional effects of DFX throughout myeloid cell maturation in both murine and human model systems. The effect of DFX depends on the stage of differentiation, with effects on mitochondrial reactive oxygen species (ROS) production and NF‐kB pathway regulation that vary between progenitors and neutrophils. DFX triggers a greater increase in mitochondrial ROS production in neutrophils and this phenomenon is mitigated when cells are cultured in hypoxic conditions. Single‐cell transcriptomic profiling revealed that DFX decreases the expression of NF‐kB and MYC (c‐Myc) targets in progenitors and decreases the expression of PU.1 (SPI1) gene targets in neutrophils. Together, these data suggest a role of DFX in impairing terminal maturation of band neutrophils. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF